The Many Shades of Plaque Psoriasis: Considerations for Treating Patients With Skin of Color

Overview

Provider Statement

This continuing education activity is provided by CMEsquared. In Partnership with the Skin of Color Society.

Support Statement

This activity is supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Intended Audience

This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.

Learning Objectives

At the completion of this activity, participants should be better able to:

• Highlight the key different clinical presentations of plaque psoriasis in skin of color (SOC)
• Review the unique treatment goals in patients with SOC that have psoriasis
• Classify the role of novel targeted agents for the management of plaque psoriasis in SOC

Faculty

Andrew Alexis, MD, MPH
Vice-Chair for Diversity and Inclusion, Dept. of Dermatology
Professor of Clinical Dermatology 
Weill Cornell Medicine
New York, NY

Mona Shahriari, MD
Dermatologist
Central CT Dermatology
Cromwell, CT

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Nevada designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

Andrew F. Alexis, MD, MPH
Grant/Research Support: BMS, LEO, Novartis, Almirall
Consultant: Leo, Galderma, Pfizer, Sanofi- Regeneron
Speakers’ Bureau or Honoraria: Regeneron, SANOFI-Genzyme, Pfizer, BMS

Mona Shahriari, MD
Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union
Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB
Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.

The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.